Paul Hartman, MD
Ophthalmology · Rochester, NYNPI 1447254917
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 25.7% of the total. Reporting peaked in 2024 at $201 and has fallen 56.7% since, to $87 in 2025. That places this record below the midpoint for ophthalmology clinicians in NY, where the typical reported total is $1,047.
Across 27 payments — averaging $23.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$160
- Alcon$125
- Sight Sciences, Inc.$99
- Thea Pharma Inc.$47
- Ivantis, Inc$36
- Glaukos Corporation$34
- plus $120 from 6 others
Across 405 payments — averaging $4430.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.1M
- Glaukos Corporation$346K
- Alcon Research LLC$128K
- Bausch Health US, LLC$120K
- Oyster Point Pharma, Inc.$65K
- Kala Pharmaceuticals, Inc.$11K
- plus $5K from 1 others
What the payments were for
- Food & beverage$621100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 9 | $160 |
| Alcon | 6 | $125 |
| Sight Sciences, Inc. | 1 | $99 |
| Thea Pharma Inc. | 2 | $47 |
| Ivantis, Inc | 2 | $36 |
| Glaukos Corporation | 1 | $34 |
| Oyster Point Pharma, Inc. | 1 | $24 |
| Bausch & Lomb Americas Inc. | 1 | $23 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
| Alcon Research LLC | 1 | $16 |
How this compares
$621 in reported general payments places this provider in the 40th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 282 | $132,326 |
| Brimonidine Tartrate | 267 | $19,647 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 63 | $16,042 |
| RhopressaNetarsudil Mesylate | 36 | $14,927 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 65 | $14,775 |
| Prednisolone Acetate | 274 | $13,988 |
| Latanoprost | 1,417 | $12,892 |
| Timolol Maleate | 670 | $12,326 |
| Bimatoprost | 118 | $11,284 |
| RocklatanNetarsudil Mesylat/Latanoprost | 19 | $8,298 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $8,188 |
| Brinzolamide | 43 | $7,007 |
| VyzultaLatanoprostene Bunod | 20 | $6,500 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 310 | $6,168 |
| Travoprost | 30 | $5,895 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $160 | $140,514298 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $17 | $23,22555 claims |
| AlconSimbrinza | $125 | $16,04263 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $23 | $6,50020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Rochester
- David KleinmanRochester$730K
- Scott MacraeRochester$74K
- David RubaltelliBrooklyn$8.9M
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- Jonathan JonischGreat Neck$726K
- Joseph PanarelliNew York$541K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.